Next Article in Journal
Genome-Wide Survey of Invertase Encoding Genes and Functional Characterization of an Extracellular Fungal Pathogen-Responsive Invertase in Glycine max
Next Article in Special Issue
Role of mTOR Signaling in Tumor Microenvironment: An Overview
Previous Article in Journal
Comparative Metagenomic Analysis of Rhizosphere Microbial Community Composition and Functional Potentials under Rehmannia glutinosa Consecutive Monoculture
Previous Article in Special Issue
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases

Biological Aspects of mTOR in Leukemia

Laboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and Psychology, Department of Clinic and Molecular Medicine, Sapienza University of Rome, via Rovigo 1, 00161 Rome, Italy
Hematology, “Sant’Andrea” University Hospital, Sapienza University of Rome, via di Grottarossa 1035, 00189 Rome, Italy
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(8), 2396;
Received: 17 July 2018 / Revised: 7 August 2018 / Accepted: 10 August 2018 / Published: 14 August 2018
(This article belongs to the Special Issue mTOR in Human Diseases)
The mammalian target of rapamycin (mTOR) is a central processor of intra- and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival. Strong evidences have indicated that mTOR dysregulation is deeply implicated in leukemogenesis. This has led to growing interest in the development of modulators of its activity for leukemia treatment. This review intends to provide an outline of the principal biological and molecular functions of mTOR. We summarize the current understanding of how mTOR interacts with microRNAs, with components of cell metabolism, and with controllers of apoptotic machinery. Lastly, from a clinical/translational perspective, we recapitulate the therapeutic results in leukemia, obtained by using mTOR inhibitors as single agents and in combination with other compounds. View Full-Text
Keywords: leukemia; cell signaling; metabolism; apoptosis; miRNA; mTOR inhibitors leukemia; cell signaling; metabolism; apoptosis; miRNA; mTOR inhibitors
Show Figures

Graphical abstract

MDPI and ACS Style

Mirabilii, S.; Ricciardi, M.R.; Piedimonte, M.; Gianfelici, V.; Bianchi, M.P.; Tafuri, A. Biological Aspects of mTOR in Leukemia. Int. J. Mol. Sci. 2018, 19, 2396.

AMA Style

Mirabilii S, Ricciardi MR, Piedimonte M, Gianfelici V, Bianchi MP, Tafuri A. Biological Aspects of mTOR in Leukemia. International Journal of Molecular Sciences. 2018; 19(8):2396.

Chicago/Turabian Style

Mirabilii, Simone, Maria R. Ricciardi, Monica Piedimonte, Valentina Gianfelici, Maria P. Bianchi, and Agostino Tafuri. 2018. "Biological Aspects of mTOR in Leukemia" International Journal of Molecular Sciences 19, no. 8: 2396.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop